Cargando…

A literature review of the promising future of TROP2: a potential drug therapy target

BACKGROUND AND OBJECTIVE: Previous studies have demonstrated that the oncogene trophoblast cell surface antigen 2 (TROP2) has great application prospects as a therapeutic target. However, few literature reviews have systematically summarized and evaluated its role in cancer therapy. This study aims...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wen, Ying, Ouyang, Dengjie, Zou, Qiongyan, Chen, Qitong, Luo, Na, He, Hongye, Anwar, Munawar, Yi, Wenjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843409/ https://www.ncbi.nlm.nih.gov/pubmed/36660684 http://dx.doi.org/10.21037/atm-22-5976

Ejemplares similares

Construction and validation of a risk prediction model for clinical axillary lymph node metastasis in T1–2 breast cancer
por: Luo, Na, et al.
Publicado: (2022)

METTL3 depletion contributes to tumour progression and drug resistance via N6 methyladenosine-dependent mechanism in HR+HER2—breast cancer
por: Ouyang, Dengjie, et al.
Publicado: (2023)

Chemotherapy significantly improves long-term survival of small lesion node negative metaplastic breast carcinoma in T1c population rather than T1a and T1b
por: Chen, Qitong, et al.
Publicado: (2022)

Targeting Trop-2 in solid tumors: future prospects
por: Zaman, Saif, et al.
Publicado: (2019)

The Expression, Functions, Interactions and Prognostic Values of PTPRZ1: A Review and Bioinformatic Analysis
por: Xia, Zhenkun, et al.
Publicado: (2019)

The anti-Trop-2 antibody-drug conjugate Sacituzumab Govitecan—effectiveness, pitfalls and promises
por: Guerra, Emanuela, et al.
Publicado: (2022)

3D reconstruction based novel methods are more effective than traditional clinical assessment in breast cancer axillary lymph node metastasis prediction
por: Qu, Limeng, et al.
Publicado: (2022)

Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers
por: Vranic, Semir, et al.
Publicado: (2022)

Clinicopathologic significance of TROP2 and phospho-TROP2 in gastric cancer
por: Kushiyama, Shuhei, et al.
Publicado: (2021)

Prognosis Comparison Between Nipple-Sparing Mastectomy and Total Mastectomy in Breast Cancer: A Case-Control Study After Propensity Score Matching
por: Fu, Mengdie, et al.
Publicado: (2021)

Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan
por: Zhao, Ming, et al.
Publicado: (2023)

Trop-2 as a Therapeutic Target in Breast Cancer
por: Sakach, Elizabeth, et al.
Publicado: (2022)

Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer
por: Shastry, Mythili, et al.
Publicado: (2022)

Trop petits pour Dieu /
por: Laederach, Monique, 1938-
Publicado: (1986)

Une trop bruyante solitude/
por: Hrabal, Bohumil, 1914-1997
Publicado: (1983)

Une fin trop précoce?
por: Rayson, Daniel
Publicado: (2022)

Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy
por: Jeong, Jae Ho, et al.
Publicado: (2022)

Identification and Characterization of Specific Nanobodies against Trop-2 for Tumor Targeting
por: Hu, Yaozhong, et al.
Publicado: (2022)

Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
por: Sperger, Jamie M., et al.
Publicado: (2023)

TROP2 modulates the progression in papillary thyroid carcinoma
por: Sun, Huali, et al.
Publicado: (2021)

Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings
por: Lombardi, Pasquale, et al.
Publicado: (2023)

Photoimmunotherapy targeting biliary‐pancreatic cancer with humanized anti‐TROP2 antibody
por: Nishimura, Takashi, et al.
Publicado: (2019)

Trop-2 in Upper Tract Urothelial Carcinoma
por: Tomiyama, Eisuke, et al.
Publicado: (2022)

Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody
por: Raji, Rhoda, et al.
Publicado: (2011)

Comparison of different drug regimens for the treatment of loiasis—A TropNet retrospective study
por: Gobbi, Federico, et al.
Publicado: (2018)

Trop2 is overexpressed in gastric cancer and predicts poor prognosis
por: Zhao, Wei, et al.
Publicado: (2015)

Impact of TROP2 expression on prognosis in solid tumors: A Systematic Review and Meta-analysis
por: Zeng, Ping, et al.
Publicado: (2016)

Trop-2 Is a Determinant of Breast Cancer Survival
por: Ambrogi, Federico, et al.
Publicado: (2014)

The Potential Diagnostic Utility of TROP-2 in Thyroid Neoplasms
por: Liu, Haiyan, et al.
Publicado: (2017)

Contrôles anti-dopage : trop, pas assez, autrement ?
por: Kintz, Pascal
Publicado: (2020)

Trop2: Jack of All Trades, Master of None
por: Lenárt, Sára, et al.
Publicado: (2020)

TROP2 Expression in Sebaceous and Sweat Gland Carcinoma
por: Ito, Takamichi, et al.
Publicado: (2022)

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
por: Goldenberg, David M., et al.
Publicado: (2015)

Antibody-drug conjugates (ADCs) targeting trophoblast cell surface antigen 2 (Trop-2) and precision treatment of breast cancer
por: Stenvang, Jan, et al.
Publicado: (2022)

Sacituzumab govitecan and other antibody-drug conjugates targeting trophoblast cell-surface antigen 2 (Trop-2) in breast cancer
por: Matusz-Fisher, Ashley, et al.
Publicado: (2022)

Amelioration of Congenital Tufting Enteropathy in EpCAM (TROP1)-Deficient Mice via Heterotopic Expression of TROP2 in Intestinal Epithelial Cells
por: Nakato, Gaku, et al.
Publicado: (2020)

TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer
por: Xu, Caili, et al.
Publicado: (2023)

The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
por: Goldenberg, David M., et al.
Publicado: (2018)

Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
por: Goldenberg, David M., et al.
Publicado: (2020)

MicroRNA-375 targets PAX6 and inhibits the viability, migration and invasion of human breast cancer MCF-7 cells
por: Zou, Qiongyan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uh4tbm0l09rig6drjcc22nbtuk